U
INSY

UBS’s Insys Therapeutics, Inc. INSY Stock Holding History

UBS’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-300
Closed -$4K – 11036
2013
Q4 		$4K Buy
+300
New +$4.16K ﹤0.01% 9763

Other funds holding INSY

JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BTP
Bloom Tree Partners New York $215M AUM 17.45% 1-Year Est. Return

UBS's INSY Position: Q3 2014 in Review

UBS increased its Insys Therapeutics, Inc. (INSY) stake by 195% in Q3 2014, buying an estimated $215K and bringing the position to 20,694 shares worth $401K. The position accounts for ﹤0.01% of the portfolio, ranked #4482.

UBS first reported a position in INSY in Q2 2013 and has held it in 5 quarters since. The position peaked at $524K in Q1 2014. 111 funds tracked by Wall St. Rank hold INSY as of Q3 2014.

  • UBS held 20,694 shares of Insys Therapeutics, Inc. worth $401K as of Q3 2014.
  • UBS bought 13,690 Insys Therapeutics, Inc. shares in Q3 2014, an estimated $215K.
  • Insys Therapeutics, Inc. made up ﹤0.01% of UBS's portfolio in Q3 2014, its #4482 holding.
  • UBS first reported a position in Insys Therapeutics, Inc. in Q2 2013 and has held it in 5 quarters since.
  • UBS's Insys Therapeutics, Inc. position peaked at $524K in Q1 2014.
  • 111 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.